Atlas Trials

Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

Clinical trial NCT04001621 · UNKNOWN

Trial details

NCT number
NCT04001621
Sponsor
Fudan University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Breast Cancer
Start date
2019-06-26
Primary completion
2023-05-31
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.